<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710630</url>
  </required_header>
  <id_info>
    <org_study_id>1160.246</org_study_id>
    <nct_id>NCT02710630</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects</brief_title>
  <official_title>Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, Five-sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the relative bioavailability of five
      different tablet formulations of Dabigatran Etexilate, Formulation A1, Formulation B1,
      Formulation C1, Formulation D1, and Formulation E1, compared to commercial capsule
      formulation of Dabigatran Etexilate.

      The secondary objective is to evaluate and compare several pharmacokinetic parameters between
      the treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Actual">June 10, 2016</completion_date>
  <primary_completion_date type="Actual">May 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Concentration of Free Dabigatran)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Plasma Concentration of Total Dabigatran)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</measure>
    <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
    <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate tablet A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate tablet B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate tablet C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate tablet D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate tablet E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate tablet E1</intervention_name>
    <arm_group_label>Dabigatran etexilate tablet E1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate tablet D1</intervention_name>
    <arm_group_label>Dabigatran etexilate tablet D1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate tablet C1</intervention_name>
    <arm_group_label>Dabigatran etexilate tablet C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate tablet B1</intervention_name>
    <arm_group_label>Dabigatran etexilate tablet B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate tablet A1</intervention_name>
    <arm_group_label>Dabigatran etexilate tablet A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate capsule</intervention_name>
    <arm_group_label>Dabigatran etexilate capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects according to the investigator's assessment, based on a complete
             medical history including a physical examination, vital signs (blood pressure [BP],
             pulse rate [PR]), 12-lead electrocardiogram (ECG), and clinical laboratory tests

          -  Age &gt;=20 and &lt;=35 years old

          -  Body mass index (BMI) &gt;=18.0 and &lt;=25.0 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          -  Any finding in the medical examination (including BP, Pulse Rate, or ECG) deviating
             from normal and judged as clinically relevant by the investigator at screening

          -  Measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic
             blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of
             45 to 90 bpm at screening

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any relevant bleeding history considered by the investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial
             medication (except appendectomy and simple hernia repair)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  Any history or evidence of blood dyscrasia, haemorrhagic diathesis, severe
             thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with
             active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary
             tract or any disease or condition with haemorrhagic tendencies

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Any evidence of a concomitant disease considered as clinically relevant by the
             investigator

          -  Intake of drugs with a long half-life (more than 24 hours) within 30 days or less than
             10 half-lives of the respective drug prior to administration of trial medication

          -  Within 10 days prior to administration of trial medication, use of drugs that might
             reasonably influence the results of the trial

          -  Intake of medication, which influences the blood clotting, e.g., acetylsalicylic acid,
             coumarin etc. within 10 days prior to trial medication

          -  Participation in another trial where an investigational drug has been administered
             within 4 months or 5 half-lives (whichever is greater) prior to planned administration
             of trial medication

          -  Planned surgeries within four weeks following the end-of study examination

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking during in-house confinement at the trial site

          -  Alcohol abuse (consumption of more than 30 g per day: e.g., 750 mL of beer, 1.5 gous
             [equivalent to 270 mL] of Sake)

          -  Drug abuse or positive drug screening

          -  Blood donation of more than 100 mL within 30 days prior to administration of trial
             medication or intended donation during the trial

          -  Intention to perform excessive physical activities within one week prior to
             administration of trial medication or during the trial

          -  Inability to comply with dietary regimen of trial site

          -  Subject assessed as unsuitable for inclusion by the investigator because of, for
             instance, being considered not able to understand and comply with study requirements,
             or having a condition that would not allow safe participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>133-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <results_first_submitted>May 8, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2017</results_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ref-A1-B1-C1-D1-E1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation A1 (TF-A1) in period 2, followed by Test Formulation B1 (TF-B1) in period 3, followed by Test Formulation C1 (TF-C1) in period 4, followed by Test Formulation D1 (TF-D1) in period 5, followed by Test Formulation E1 (TF-E1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="P2">
          <title>Ref-B1-C1-D1-E1-A1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation B1 (TF-B1) in period 2, followed by Test Formulation C1 (TF-C1) in period 3, followed by Test Formulation D1 (TF-D1) in period 4, followed by Test Formulation E1 (TF-E1) in period 5, followed by Test Formulation A1 (TF-A1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="P3">
          <title>Ref-C1-D1-E1-A1-B1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation C1 (TF-C1) in period 2, followed by Test Formulation D1 (TF-D1) in period 3, followed by Test Formulation E1 (TF-E1) in period 4, followed by Test Formulation A1 (TF-A1) in period 5, followed by Test Formulation B1 (TF-B1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="P4">
          <title>Ref-D1-E1-A1-B1-C1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation D1 (TF-D1) in period 2, followed by Test Formulation E1 (TF-E1) in period 3, followed by Test Formulation A1 (TF-A1) in period 4, followed by Test Formulation B1 (TF-B1) in period 5, followed by Test Formulation C1 (TF-C1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="P5">
          <title>Ref-E1-A1-B1-C1-D1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation E1 (TF-E1) in period 2, followed by Test Formulation A1 (TF-A1) in period 3, followed by Test Formulation B1 (TF-B1) in period 4, followed by Test Formulation C1 (TF-C1) in period 5, followed by Test Formulation D1 (TF-D1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This set included all subjects that were dispensed study drug and were documented to have taken at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Ref-A1-B1-C1-D1-E1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation A1 (TF-A1) in period 2, followed by Test Formulation B1 (TF-B1) in period 3, followed by Test Formulation C1 (TF-C1) in period 4, followed by Test Formulation D1 (TF-D1) in period 5, followed by Test Formulation E1 (TF-E1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="B2">
          <title>Ref-B1-C1-D1-E1-A1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation B1 (TF-B1) in period 2, followed by Test Formulation C1 (TF-C1) in period 3, followed by Test Formulation D1 (TF-D1) in period 4, followed by Test Formulation E1 (TF-E1) in period 5, followed by Test Formulation A1 (TF-A1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="B3">
          <title>Ref-C1-D1-E1-A1-B1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation C1 (TF-C1) in period 2, followed by Test Formulation D1 (TF-D1) in period 3, followed by Test Formulation E1 (TF-E1) in period 4, followed by Test Formulation A1 (TF-A1) in period 5, followed by Test Formulation B1 (TF-B1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="B4">
          <title>Ref-D1-E1-A1-B1-C1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation D1 (TF-D1) in period 2, followed by Test Formulation E1 (TF-E1) in period 3, followed by Test Formulation A1 (TF-A1) in period 4, followed by Test Formulation B1 (TF-B1) in period 5, followed by Test Formulation C1 (TF-C1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="B5">
          <title>Ref-E1-A1-B1-C1-D1</title>
          <description>All subjects were treated with the reference treatment (Ref), Dabigatran Etexilate (BIBR 1048) commercial capsule formulation, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours in period 1, followed by one of the 5 investigational treatment in the following sequence, i.e., test formulation Dabigatran Etexilate tablet formulations in the sequence Test Formulation E1 (TF-E1) in period 2, followed by Test Formulation A1 (TF-A1) in period 3, followed by Test Formulation B1 (TF-B1) in period 4, followed by Test Formulation C1 (TF-C1) in period 5, followed by Test Formulation D1 (TF-D1) in period 6, 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.
A washout period of at least 4 days was set following the drug administration in each period.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="2.4"/>
                    <measurement group_id="B2" value="28.1" spread="3.4"/>
                    <measurement group_id="B3" value="27.3" spread="3.4"/>
                    <measurement group_id="B4" value="29.1" spread="3.6"/>
                    <measurement group_id="B5" value="27.4" spread="3.4"/>
                    <measurement group_id="B6" value="27.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
        <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): This analysis set included all subjects of the treated set who provided at least one primary or secondary PK parameter. Thus, a subject was included in the PKS, even if the subject contributed only one PK parameter value for one period to the statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
          <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): This analysis set included all subjects of the treated set who provided at least one primary or secondary PK parameter. Thus, a subject was included in the PKS, even if the subject contributed only one PK parameter value for one period to the statistical assessment.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" spread="51.8"/>
                    <measurement group_id="O2" value="714" spread="42.1"/>
                    <measurement group_id="O3" value="318" spread="327"/>
                    <measurement group_id="O4" value="354" spread="96.6"/>
                    <measurement group_id="O5" value="649" spread="78.6"/>
                    <measurement group_id="O6" value="661" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>119.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.838</ci_lower_limit>
            <ci_upper_limit>139.834</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>52.97</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>168.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.341</ci_lower_limit>
            <ci_upper_limit>84.158</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>59.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>73.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.255</ci_lower_limit>
            <ci_upper_limit>76.955</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>108.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>55.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.698</ci_lower_limit>
            <ci_upper_limit>133.530</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>110.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.939</ci_lower_limit>
            <ci_upper_limit>129.297</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Concentration of Free Dabigatran)</title>
        <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): This analysis set included all subjects of the treated set who provided at least one primary or secondary PK parameter. Thus, a subject was included in the PKS, even if the subject contributed only one PK parameter value for one period to the statistical assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Concentration of Free Dabigatran)</title>
          <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): This analysis set included all subjects of the treated set who provided at least one primary or secondary PK parameter. Thus, a subject was included in the PKS, even if the subject contributed only one PK parameter value for one period to the statistical assessment.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="60.0"/>
                    <measurement group_id="O2" value="86.8" spread="39.3"/>
                    <measurement group_id="O3" value="42.3" spread="213"/>
                    <measurement group_id="O4" value="45.5" spread="81.5"/>
                    <measurement group_id="O5" value="79.6" spread="73.5"/>
                    <measurement group_id="O6" value="79.2" spread="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>118.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>44.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.569</ci_lower_limit>
            <ci_upper_limit>140.579</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>57.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>132.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.502</ci_lower_limit>
            <ci_upper_limit>85.837</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>61.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>69.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.130</ci_lower_limit>
            <ci_upper_limit>79.720</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>108.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>55.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.704</ci_lower_limit>
            <ci_upper_limit>133.629</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>107.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.238</ci_lower_limit>
            <ci_upper_limit>127.281</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</title>
        <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</title>
          <description>This outcome measure presents area under the concentration-time curve of free Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623" spread="49.0"/>
                    <measurement group_id="O2" value="735" spread="40.2"/>
                    <measurement group_id="O3" value="544" spread="71.9"/>
                    <measurement group_id="O4" value="444" spread="60.3"/>
                    <measurement group_id="O5" value="725" spread="53.0"/>
                    <measurement group_id="O6" value="684" spread="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>118.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.627</ci_lower_limit>
            <ci_upper_limit>137.621</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>87.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>60.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.404</ci_lower_limit>
            <ci_upper_limit>109.722</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>71.40</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>49.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.828</ci_lower_limit>
            <ci_upper_limit>86.648</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>116.67</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.516</ci_lower_limit>
            <ci_upper_limit>135.410</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>109.85</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.452</ci_lower_limit>
            <ci_upper_limit>127.750</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
        <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
          <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 to the time of the last quantifiable data point.</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726" spread="52.9"/>
                    <measurement group_id="O2" value="838" spread="41.1"/>
                    <measurement group_id="O3" value="366" spread="341"/>
                    <measurement group_id="O4" value="412" spread="97.1"/>
                    <measurement group_id="O5" value="777" spread="74.9"/>
                    <measurement group_id="O6" value="778" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>115.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.783</ci_lower_limit>
            <ci_upper_limit>135.491</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>50.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>173.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.519</ci_lower_limit>
            <ci_upper_limit>80.689</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>56.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>74.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.388</ci_lower_limit>
            <ci_upper_limit>74.122</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>106.99</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>52.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.554</ci_lower_limit>
            <ci_upper_limit>130.732</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>107.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.399</ci_lower_limit>
            <ci_upper_limit>125.432</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Plasma Concentration of Total Dabigatran)</title>
        <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Plasma Concentration of Total Dabigatran)</title>
          <description>This outcome measure presents maximum concentration of analyte in plasma (Cmax).</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" spread="62.0"/>
                    <measurement group_id="O2" value="102" spread="39.0"/>
                    <measurement group_id="O3" value="47.9" spread="227"/>
                    <measurement group_id="O4" value="52.2" spread="83.6"/>
                    <measurement group_id="O5" value="94.2" spread="75.7"/>
                    <measurement group_id="O6" value="91.9" spread="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>115.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>45.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.740</ci_lower_limit>
            <ci_upper_limit>137.644</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>54.12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>138.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.818</ci_lower_limit>
            <ci_upper_limit>81.774</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>58.96</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>71.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.489</ci_lower_limit>
            <ci_upper_limit>76.431</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>106.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>57.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.846</ci_lower_limit>
            <ci_upper_limit>131.836</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>103.73</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.740</ci_lower_limit>
            <ci_upper_limit>122.628</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</title>
        <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
        <time_frame>1:00 [hour (h): minute] before drug administration and 1:00h, 1:30h, 2:00h, 3:00h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h, 48:00h after drug administration.</time_frame>
        <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate Capsule: Ref</title>
            <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate Tablet: A1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate Tablet: B1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate Tablet: C1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O5">
            <title>Dabigatran Etexilate Tablet: D1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O6">
            <title>Dabigatran Etexilate Tablet: E1</title>
            <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)</title>
          <description>This outcome measure presents area under the concentration-time curve of total Dabigatran in plasma over the time interval from 0 extrapolated to infinity)(if applicable).</description>
          <population>The PharmacoKinetic (PK) parameter analysis Set (PKS): Included all subjects of the treated set who provided at least one primary or secondary PK parameter.
PK Set 2 (PKS2): Included all subjects in the PKS who had evaluable PK variable of the reference treatment and at least one of the 5 test treatments.
PKS2 was used for statistical analyses.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="750" spread="50.5"/>
                    <measurement group_id="O2" value="863" spread="39.1"/>
                    <measurement group_id="O3" value="628" spread="75.6"/>
                    <measurement group_id="O4" value="515" spread="60.1"/>
                    <measurement group_id="O5" value="804" spread="70.1"/>
                    <measurement group_id="O6" value="800" spread="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>115.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.063</ci_lower_limit>
            <ci_upper_limit>134.130</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: A1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>83.73</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>62.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.033</ci_lower_limit>
            <ci_upper_limit>106.163</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: B1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>68.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>50.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.452</ci_lower_limit>
            <ci_upper_limit>83.782</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: C1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>107.13</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>49.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.616</ci_lower_limit>
            <ci_upper_limit>129.510</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: D1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio [Test/Reference]</param_type>
            <param_value>106.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>38.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.625</ci_lower_limit>
            <ci_upper_limit>124.114</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean (gMean) ratio [%] calculated as Dabigatran Etexilate Tablet: E1/Dabigatran Etexilate Capsule: Ref.
Standard deviation is actually intra-individual geometric coefficient of variation (gCV) [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 1 day after last drug administration, up to 81 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate Capsule: Ref</title>
          <description>The subjects received Dabigatran Etexilate (Reference) capsule formulation (commercial formulation) 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate Tablet: A1</title>
          <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (A1), 110 mg orally (one day, single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E3">
          <title>Dabigatran Etexilate Tablet: B1</title>
          <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (B1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E4">
          <title>Dabigatran Etexilate Tablet: C1</title>
          <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (C1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E5">
          <title>Dabigatran Etexilate Tablet: D1</title>
          <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (D1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E6">
          <title>Dabigatran Etexilate Tablet: E1</title>
          <description>The subjects received Dabigatran Etexilate (Test) tablet formulation (E1), 110 mg orally (one day single dose) with 200 mL of water after an overnight fast of at least 10 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

